EU Approves Merck’s Ebola Vaccine

The European Commission granted a conditional marketing authorization to Merck’s Ervebo for immunization of patients 18 years of age or older to protect against Ebola virus disease.

Valid in the 28 EU member countries and in the European Economic Area, the approval allows Merck to begin manufacturing licensed doses in Germany, which are expected to become available in the third quarter of 2020.

Ervebo is currently under priority review by the FDA and has a target action date of March 14, 2020.